Dr. Kunkel has more than two decades of experience in oncology and immunology drug development and commercialization. Dr. Kunkel presently serves on the Board of Directors of Enliven Therapeutics, Nurix Therapeutics, and Oric Pharmaceuticals.  She was previously the acting Chief Medical Officer and served on the board of Loxo Oncology (sold to Eli Lilly).  She has previously  served on the board of directors of Curis Inc., Maverick Therapeutics, Harpoon Therapeutics and Tocagen. She was formerly Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and CMO at Proteolix, Inc. (acquired by Onyx Pharmaceuticals), where she contributed to the global approvals of cancer therapeutics IMBRUVICA® and Kyprolis®, respectively.  Prior to joining the biotechnology industry, Dr. Kunkel spent ten years in academic medicine and served as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at University of California, Los Angeles.